Latest erythema Stories
-- Latest psychological research reveals rosacea redness creates negative first impressions putting sufferers at a disadvantage -- Rosacea remains under-diagnosed, yet diagnosis
MALVERN, Pa., Aug.
Incyte Corporation (Nasdaq:INCY) reported positive results from two 28-day Phase IIa clinical trials of topical INCB18424, a selective janus-associated kinase (JAK) inhibitor, in patients with mild to moderate psoriasis.
By Dr. Helen Minciotti Mom and dad showed up on time for their newborn's first outpatient exam. That was already quite an accomplishment, considering the packing and infant bundling needed before venturing out in the frigid winter air.
Merck & Co., Inc. announced today that the US Food and Drug Administration (FDA) has issued a complete response letter regarding the supplemental biologics license application (sBLA) for the use of GARDASIL(R) in women ages 27 though 45.